SCHEMBL23244628

SCHEMBL23244628

CCN(CC)c1ccc2nc3c4ccc(-c5ccc(C#N)cc5)cc4c(=O)cc-3oc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
NPC1 O15118 1/20 0.67
POLB P06746 1/20 0.67
RAB9A P51151 1/20 0.67
SCP2 P22307 1/20 0.53
KDM4E B2RXH2 5/20 0.43
MAPT P10636 4/20 0.43
GPR84 Q9NQS5 10/20 0.42
PGR P06401 1/20 0.42
TNKS O95271 1/20 0.41
ALDH1A1 P00352 4/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HIF1A Q16665 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTT P42858 2/20 0.38
TP53 P04637 1/20 0.38
ALOX15 P16050 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23244637 0.96 MEN1 (0.67) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL15398222 0.88 MEN1 (0.78) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL15398206 0.88 MEN1 (0.78) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL23244667 0.87 MEN1 (0.70) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL23266942 0.84 MEN1 (0.78) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL23244676 0.83 MEN1 (0.70) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL23266941 0.82 MEN1 (0.74) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL16345691 0.81 MEN1 (0.67) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL4664437 0.81 MEN1 (0.76) MEN1KMT2ANPC1POLBRAB9A
Nile Red SCHEMBL49047 0.81 MEN1 (1.00) MEN1KMT2ANPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210115000-A1 NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRAST THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2021-04-22 US claimed
US-20210115000-A1 NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRAST THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2021-04-22 US disclosed
US-20210115000-A1 NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRAST THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2021-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115000-A1 NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRAST FABP4, LRBA, FABP7 MEN1 3010/4885KMT2A 4468/4885NPC1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.